These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22429138)

  • 1. Simple and general criterion for "in silico" screening of candidate HIV drugs.
    Veljkovic N; Glisic S; Prljic J; Perovic V; Veljkovic V
    Curr Pharm Biotechnol; 2013; 14(5):561-9. PubMed ID: 22429138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
    Barbaro G; Scozzafava A; Mastrolorenzo A; Supuran CT
    Curr Pharm Des; 2005; 11(14):1805-43. PubMed ID: 15892677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the EIIP/ISM bioinformatics concept in development of new drugs.
    Veljkovic V; Veljkovic N; Esté JA; Hüther A; Dietrich U
    Curr Med Chem; 2007; 14(4):441-53. PubMed ID: 17305545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.
    Mastrolorenzo A; Rusconi S; Scozzafava A; Barbaro G; Supuran CT
    Curr Med Chem; 2007; 14(26):2734-48. PubMed ID: 18045120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20).
    Manfredi R; Sabbatani S
    Curr Med Chem; 2006; 13(20):2369-84. PubMed ID: 16918361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of new reverse transcriptase inhibitors].
    Kodama E
    Nihon Rinsho; 2002 Apr; 60(4):775-9. PubMed ID: 11968787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HIV therapy: Current and future directions.
    Agrawal L; Lu X; Jin Q; Alkhatib G
    Curr Pharm Des; 2006; 12(16):2031-55. PubMed ID: 16787246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
    Sierra-Aragón S; Walter H
    Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.
    Menéndez-Arias L; Alvarez M
    Antiviral Res; 2014 Feb; 102():70-86. PubMed ID: 24345729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.